Skip to content

Search

T-cell activation genes differentially expressed at birth in CD4+ T-cells from children who develop IgE food allergy

To show underlying mechanisms, we examined differences in T-cell gene expression in samples at birth and at 1 year in children with and without IgE allergy.

The relationship between maternal folate status in pregnancy, cord blood folate levels, and allergic outcomes in early childhood

This study examined whether maternal and/or fetal folate status in pregnancy is associated with infant allergic outcomes.

Does genetic regulation of IgE begin in utero?

Elucidation of early life factors is critical to understand the development of allergic diseases, especially those manifesting in early life such as food allerg

Role of antenatal maternal diet

Nutrition is a modifiable lifestyle factor that may play a role in allergic disease prevention. This article summarizes current evidence on the antenatal diet as a consideration for strategies to prevent child food allergy. As eczema in early infancy substantially increases the risk of food allergy development, the effects of maternal dietary intakes during pregnancy on infant eczema outcomes will also be discussed.

Impaired calcium influx underlies skewed T helper cell differentiation in children with IgE-mediated food allergies

Reasons for Th2 skewing in IgE-mediated food allergies remains unclear. Clinical observations suggest impaired T cell activation may drive Th2 responses evidenced by increased atopic manifestations in liver transplant patients on tacrolimus (a calcineurin inhibitor). We aimed to assess differentiation potential, T cell activation and calcium influx of naïve CD4+ T cells in children with IgE-mediated food allergies. 

Two-year post-treatment outcomes following peanut oral immunotherapy in the Probiotic and Peanut Oral Immunotherapy-003 Long-Term (PPOIT-003LT) study

Few studies have examined long-term outcomes following oral immunotherapy; none have examined long-term risks and benefits associated with distinct clinical outcomes (desensitization, remission).

Early Peanut Immunotherapy in Children (EPIC) trial: Protocol for a pragmatic randomised controlled trial of peanut oral immunotherapy in children under 5 years of age

Food allergy is a major public health challenge in Australia. Despite widespread uptake of infant feeding and allergy prevention guidelines the incidence of peanut allergy in infants has not fallen, and prevalence of peanut allergy in school-aged children continues to rise. Therefore, effective and accessible treatments for peanut allergy are required.